HOME >> MEDICINE >> NEWS
ENBREL (Etanercept) Patient And Physician Support Web Site Launched

Web Site Offers Important Information And Support Programs For People With Rheumatoid Arthritis And For Their Health Care Providers

SEATTLE, April 6, 1999 - In an effort to better educate patients and health care providers about ENBREL (etanercept), a breakthrough treatment for rheumatoid arthritis (RA), Immunex Corporation and Wyeth-Ayerst Pharmaceuticals have launched the ENBREL Web Site: www.enbrel.com. ENBREL is used to treat moderately to severely active rheumatoid arthritis in people who have not adequately responded to one or more disease-modifying anti-rheumatic drugs (DMARDs).

The comprehensive internet site explains how ENBREL works in the body, offers a question and answer section, provides an interactive quiz to help RA sufferers and their doctors determine if ENBREL may be right for them, and highlights several patients' personal experiences with ENBREL. Color photography and animation add to the graphic interest of the site.

Enbrel.com also offers two toll-free numbers to provide support to patients who are considering or are currently taking ENBREL. For questions about insurance coverage, patients can call the Reimbursement Support Line (1-800-282-7704) where they will be connected with an insurance specialist. To answer any noninsurance questions about ENBREL and RA in general, trained telephone counselors are available at 1-888-4ENBREL. A link to the Arthritis Foundation Web Site is also provided.

Approximately 2.1 million Americans suffer from rheumatoid arthritis, an autoimmune disease that can strike at any age and affects three times as many women as men. ENBREL is the first in a class of rheumatoid arthritis drugs known as biologic response modifiers (BRMs), a new approach to RA management and the first breakthrough treatment in many years for people with rheumatoid arthritis.

In medical studies, just over one third of people treated with ENBREL (etanercept) rep
'"/>

Contact: Tim Warner
warnert@immunex.com
206-470-4193
Immunex Corporation
6-Apr-1999


Page: 1 2

Related medicine news :

1. ENBREL (etanercept) long-term clinical trial data
2. ENBREL application for early, active rheumatoid arthritis filed with the U.S. Food and Drug Administration
3. Circulation publishes phase I study of ENBREL in patients with chronic heart failure
4. ENBREL (Etanercept) Receives FDA Approval For Treatment Of Juvenile Rheumatoid Arthritis
5. Positive Results Of Pivotal Phase III Trial With ENBREL In Patients With Early, Active Rheumatoid Arthritis
6. ENBREL Phase III Data Published In Annals Of Internal Medicine
7. Patients newly diagnosed with HIV are more likely to enter outpatient care with case management
8. Patient with drug-resistant form of HIV identified
9. Patient knows best when it comes to ulcerative colitis, U-M study finds
10. Patients with cancer have highly increased risk for blood clots
11. Patients with previous heart attacks may not benefit from pacemaker implant

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... ... ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a weight ... app plans to fix the two major problems leading the fitness industry today:, ... program , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... inhaled drugs, announced today that it was added to ... its comprehensive set of U.S. and global equity ... an important milestone for Pulmatrix," said Chief Executive Officer ... of our progress in developing drugs for crucial unmet ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
Breaking Medicine Technology:
Cached News: